Loading…
CELZ stock experiences a surge following the announcement.
Creative Medical Technology Holdings, Inc. (Nasdaq: CELZ) announced the acquisition of a new patent related to diabetes treatment, which has fueled positive momentum for the company. The announcement was made public recently, leading to a noticeable surge in CELZ stock.
The new patent is expected to enhance the company's portfolio in diabetes treatment solutions. With a free float of 3,431,400 shares, the market has responded positively to this development.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.